Immuno Mycologies Inc.

Immuno Mycologies Inc., a for-profit manufacturer of diagnostic products headquartered in Norman, Oklahoma, supplies fungal disease detection reagents and test kits to the Department of Veterans Affairs as a prime contractor (74% of recent awards) and as a subcontractor to international health programs routed through Chemonics International. The vendor competes full-and-open with no set-aside designations across its prime footprint.

Immuno Mycologies manufactures in-vitro diagnostic substances—specifically fungal complement fixation and immunodiffusion testing controls, coccidiosis antibody reagent test kits, and cryptococcal antigen lateral flow assays—in support of fungal disease detection within federal healthcare and research programs. Representative prime work includes a $1.5 million Phase II Small Business Innovation Research contract from the National Institute of Allergy and Infectious Diseases (awarded September 2022, completing September 2025) for development and validation of an enzyme immunoassay to detect Talaromyces marneffei antigen; a $1.43 million Blanket Purchase Agreement ceiling with Veterans Integrated Service Network 22 for coccidiosis antibody reagent test kits (awarded June 2022, extending through June 2027, with five task orders placed totaling $874 thousand); and a $657 thousand BPA ceiling with VISN 9 for complement fixation and immunodiffusion testing supplies (awarded January 2026, extending through January 2031).

Customer concentration splits between domestic federal healthcare and international health security. The VA dominates the prime customer base by dollar value—VISN 22 and VISN 9 together account for $3.8 million in combined potential value across 15 awards—while the U.S. Agency for International Development Bureau for Global Health represents the largest award count at 23 sub-awards, all routed through Chemonics International for HIV/AIDS and supply-chain programs in sub-Saharan Africa, the Caribbean, and Eastern Europe. The National Institute of Allergy and Infectious Diseases contributes $1.7 million in combined potential value across three research awards. Top customers by count and dollars account for 52% and 99% of the award portfolio respectively, signaling concentration in a narrow customer set.

Immuno Mycologies holds three parent indefinite delivery vehicles. The USAID IDIQ (AIDOAAI1500004) anchors 23 task orders routed through Chemonics; the VA VISN 22 BPA (36C26222A0042) carries 5 task orders valued at $874 thousand; and the VA VISN 9 IDC (36C24924D0034) and BPA (36C24926A0032) together support 2 task orders valued at $266 thousand. Activity has tracked uneven across the past five years—6 awards in 2022, 8 in 2023, 12 in 2024, 6 in 2025, and 4 in 2026 year-to-date—with minimal recompete exposure over the next twenty-four months (two awards, $244 thousand combined potential value).

As a subcontractor, Immuno Mycologies supplies cryptococcal antigen lateral flow assays to Chemonics International under the Global Health Supply Chain–Program Support Management (GHSC-PSM) IDIQ, with 21 sub-awards spanning 2022 through May 2026 for field distribution across Uganda, Nigeria, Haiti, the Democratic Republic of Congo, Zambia, and Ukraine in support of HIV/AIDS diagnostics and treatment programs funded through USAID. The vendor operates entirely as an internal delivery team on its prime contracts; SCI reporting across FY2022–FY2024 shows $515 thousand in invoiced federal service revenue and a negligible FTE footprint (0.1 FTEs recorded in FY2023), with government-paid hourly rates on prime contracts running a median of $2,729/hr and ranging from $2,146/hr to $3,313/hr across the 10th to 90th percentile. This rate posture and minimal sub-engagement reflect the vendor's positioning as a product manufacturer and supplier rather than a labor-intensive service provider.